Kết quả điều trị ung thư tuyến tiền liệt di căn bằng liệu pháp ức chế Androgen

Evaluation of the treatment results of metastatic prostate cancer with androgen deprivation therapy. Patients and methods: Retrospective cross-sectional study of 40 patients diagnosed with metastatic prostate cancer treated with Androgen inhibition therapy at Nghe An Oncology Hospital from January 1, 2018 to January 1, 2023. Results: Clinical characteristics at the time of diagnosis: bone pain (66.1%), insomnia (62.5%), dysuria (39.3%), 83.9% of patients had PSA levels >100ng/mL, bone metastasis (94.6%), lymph node metastasis (64.3%), patients with surgical orchiectomy (46.4%), patients with medical orchiectomy (53.6%). PSA levels were lowest after 3 months. Median progression-free survival (PFS) was 24.8±1.9 months, PFS in the surgical orchiectomy group was 20.8±1.5 months, PFS in the medical orchiectomy group was 29.8±3.3 months, the difference was not statistically significant. Conclusion: Androgen deprivation therapy is a fundamental, consistent and effective treatment in metastatic prostate cancer.